ONCAlert | 2017 San Antonio Breast Cancer Symposium

Preliminary Results of Coxsackievirus With Pembrolizumab In Advanced Melanoma

Ann W. Silk, MD
Published Online:10:25 AM, Mon April 10, 2017

Ann W. Silk, MD, assistant professor, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine, discusses preliminary results of the CAPRA trial, a phase 1B study of intratumoral coxsackievirus A21 (CVA21; CAVATAK) and systemic pembrolizumab in patients with advanced melanoma.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.